93 related articles for article (PubMed ID: 23531193)
1. Impact of PLK-1 silencing on endothelial cells and cancer cells of diverse histological origin.
Gomes CP; Gomes-da-Silva LC; Ramalho JS; de Lima MC; Simões S; Moreira JN
Curr Gene Ther; 2013 Jun; 13(3):189-201. PubMed ID: 23531193
[TBL] [Abstract][Full Text] [Related]
2. Impact of anti-PLK1 siRNA-containing F3-targeted liposomes on the viability of both cancer and endothelial cells.
Gomes-da-Silva LC; Ramalho JS; Pedroso de Lima MC; Simões S; Moreira JN
Eur J Pharm Biopharm; 2013 Nov; 85(3 Pt A):356-64. PubMed ID: 23659854
[TBL] [Abstract][Full Text] [Related]
3. RNA interference-mediated silencing of the polo-like kinase 1 gene enhances chemosensitivity to gemcitabine in pancreatic adenocarcinoma cells.
Yu C; Zhang X; Sun G; Guo X; Li H; You Y; Jacobs JL; Gardner K; Yuan D; Xu Z; Du Q; Dai C; Qian Z; Jiang K; Zhu Y; Li QQ; Miao Y
J Cell Mol Med; 2008 Dec; 12(6A):2334-49. PubMed ID: 18266952
[TBL] [Abstract][Full Text] [Related]
4. Silencing of polo-like kinase (Plk) 1 via siRNA causes induction of apoptosis and impairment of mitosis machinery in human prostate cancer cells: implications for the treatment of prostate cancer.
Reagan-Shaw S; Ahmad N
FASEB J; 2005 Apr; 19(6):611-3. PubMed ID: 15661849
[TBL] [Abstract][Full Text] [Related]
5. PLK-1 Silencing in Bladder Cancer by siRNA Delivered With Exosomes.
Greco KA; Franzen CA; Foreman KE; Flanigan RC; Kuo PC; Gupta GN
Urology; 2016 May; 91():241.e1-7. PubMed ID: 26876462
[TBL] [Abstract][Full Text] [Related]
6. Polo-like kinase 1 is a potential therapeutic target in human melanoma.
Jalili A; Moser A; Pashenkov M; Wagner C; Pathria G; Borgdorff V; Gschaider M; Stingl G; Ramaswamy S; Wagner SN
J Invest Dermatol; 2011 Sep; 131(9):1886-95. PubMed ID: 21654832
[TBL] [Abstract][Full Text] [Related]
7. siRNA targeting PLK-1 induces apoptosis of synoviocytes in rheumatoid arthritis.
Wada M; Kawahito Y; Kimura S; Kohno M; Ishino H; Kimura M; Omoto A; Yamamoto A; Hamaguchi M; Tsubouchi Y; Tokunaga D; Hojo T; Ashihara E; Maekawa T; Yoshikawa T
Biochem Biophys Res Commun; 2007 Jun; 357(2):353-9. PubMed ID: 17434144
[TBL] [Abstract][Full Text] [Related]
8. PSA-responsive and PSMA-mediated multifunctional liposomes for targeted therapy of prostate cancer.
Xiang B; Dong DW; Shi NQ; Gao W; Yang ZZ; Cui Y; Cao DY; Qi XR
Biomaterials; 2013 Sep; 34(28):6976-91. PubMed ID: 23777916
[TBL] [Abstract][Full Text] [Related]
9. Therapeutic targeting of polo-like kinase 1 using RNA-interfering nanoparticles (iNOPs) for the treatment of non-small cell lung cancer.
McCarroll JA; Dwarte T; Baigude H; Dang J; Yang L; Erlich RB; Kimpton K; Teo J; Sagnella SM; Akerfeldt MC; Liu J; Phillips PA; Rana TM; Kavallaris M
Oncotarget; 2015 May; 6(14):12020-34. PubMed ID: 25557168
[TBL] [Abstract][Full Text] [Related]
10. Rational combinations of siRNAs targeting Plk1 with breast cancer drugs.
Spänkuch B; Kurunci-Csacsko E; Kaufmann M; Strebhardt K
Oncogene; 2007 Aug; 26(39):5793-807. PubMed ID: 17369857
[TBL] [Abstract][Full Text] [Related]
11. Tubulin-binding agents down-regulate matrix metalloproteinase-2 and -9 in human hormone-refractory prostate cancer cells – a critical role of Cdk1 in mitotic entry.
Chang WL; Yu CC; Chen CS; Guh JH
Biochem Pharmacol; 2015 Mar; 94(1):12-21. PubMed ID: 25615907
[TBL] [Abstract][Full Text] [Related]
12. Analyses of expressions and prognostic values of Polo-like kinases in non-small cell lung cancer.
Zeng Y; Li N; Liu W; Zeng M; Cheng J; Huang J
J Cancer Res Clin Oncol; 2020 Oct; 146(10):2447-2460. PubMed ID: 32627077
[TBL] [Abstract][Full Text] [Related]
13. Administration of PLK-1 small interfering RNA with atelocollagen prevents the growth of liver metastases of lung cancer.
Kawata E; Ashihara E; Kimura S; Takenaka K; Sato K; Tanaka R; Yokota A; Kamitsuji Y; Takeuchi M; Kuroda J; Tanaka F; Yoshikawa T; Maekawa T
Mol Cancer Ther; 2008 Sep; 7(9):2904-12. PubMed ID: 18790771
[TBL] [Abstract][Full Text] [Related]
14. Intravesical administration of small interfering RNA targeting PLK-1 successfully prevents the growth of bladder cancer.
Nogawa M; Yuasa T; Kimura S; Tanaka M; Kuroda J; Sato K; Yokota A; Segawa H; Toda Y; Kageyama S; Yoshiki T; Okada Y; Maekawa T
J Clin Invest; 2005 Apr; 115(4):978-85. PubMed ID: 15761500
[TBL] [Abstract][Full Text] [Related]
15. Silencing of polo-like kinase (Plk) 1 via siRNA causes inhibition of growth and induction of apoptosis in human esophageal cancer cells.
Bu Y; Yang Z; Li Q; Song F
Oncology; 2008; 74(3-4):198-206. PubMed ID: 18714168
[TBL] [Abstract][Full Text] [Related]
16. Apoptotic effects of genistein, biochanin-A and apigenin on LNCaP and PC-3 cells by p21 through transcriptional inhibition of polo-like kinase-1.
Seo YJ; Kim BS; Chun SY; Park YK; Kang KS; Kwon TG
J Korean Med Sci; 2011 Nov; 26(11):1489-94. PubMed ID: 22065906
[TBL] [Abstract][Full Text] [Related]
17. RNAse A-like enzymes in serum inhibit the anti-neoplastic activity of siRNA targeting polo-like kinase 1.
Haupenthal J; Baehr C; Zeuzem S; Piiper A
Int J Cancer; 2007 Jul; 121(1):206-10. PubMed ID: 17351902
[TBL] [Abstract][Full Text] [Related]
18. Epithelial-Mesenchymal Transition Predicts Polo-Like Kinase 1 Inhibitor-Mediated Apoptosis in Non-Small Cell Lung Cancer.
Ferrarotto R; Goonatilake R; Yoo SY; Tong P; Giri U; Peng S; Minna J; Girard L; Wang Y; Wang L; Li L; Diao L; Peng DH; Gibbons DL; Glisson BS; Heymach JV; Wang J; Byers LA; Johnson FM
Clin Cancer Res; 2016 Apr; 22(7):1674-1686. PubMed ID: 26597303
[TBL] [Abstract][Full Text] [Related]
19. miR-296-5p suppresses cell viability by directly targeting PLK1 in non-small cell lung cancer.
Xu C; Li S; Chen T; Hu H; Ding C; Xu Z; Chen J; Liu Z; Lei Z; Zhang HT; Li C; Zhao J
Oncol Rep; 2016 Jan; 35(1):497-503. PubMed ID: 26549165
[TBL] [Abstract][Full Text] [Related]
20. Blocking Mitotic Exit of Ovarian Cancer Cells by Pharmaceutical Inhibition of the Anaphase-Promoting Complex Reduces Chromosomal Instability.
Raab M; Sanhaji M; Zhou S; Rödel F; El-Balat A; Becker S; Strebhardt K
Neoplasia; 2019 Apr; 21(4):363-375. PubMed ID: 30851646
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
